Clinical trials: Asthma Patients
Asthma
Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma
This is a study to establish the equivalence of OT329 Solis and Advair Diskus when administered by inhalation in patients with asthma.
- Trial name
- NCT02260492
- Testing
- OT329 (combination of fluticasone propionate and salmeterol xinafoate), Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)
- Where
- 47 sites in United States
- Volunteers
- 879 people
- Sponsor
- Oriel Therapeutics
Asthma
Correct Use of Sequential Formoterol and Budesonide Inhaler Capsule Treatment Via Aerolizer and Patient Satisfaction in Asthmatics
This study will evaluate the correct use of sequential formoterol and budesonide inhaler capsule treatment via Aerolizer and patient satisfaction in adult asthmatics.
- Trial name
- NCT00997477
- Testing
- Foradil Combi (Formoterol-budesonide)
- Where
- 4 sites in Turkey (Türkiye)
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer, Emphysema
CryoSpray Ablation(tm)Thoracic Patient Registry
The purpose of this study is to create a patient registry to collect and analyze information on subjects treated with the CryoSpray Ablation™ System post-510K approval.
- Conditions
- Lung Cancer, Emphysema, Chronic Bronchitis, COPD
- Trial name
- NCT00785239
- Sponsor
- CSA Medical, Inc.
Pulmonary Disease, Chronic Obstructive
Repeat Doses Of A New Medication (GW642444) In Asthmatic Patients
In order to obtain information on a wider range of doses of GW642444 (a possible new medication to treat asthma) than has been previously examined in asthmatic patients, this current study will be conducted at doses of 25 100 and…
- Trial name
- NCT00347139
- Testing
- GW642444 (25, 100 & 400 mcg/day), Salmeterol 50mcg
- Where
- 7 sites in Germany, New Zealand and 3 more
- Volunteers
- 55 people
- Sponsor
- GlaxoSmithKline
Asthma
Montelukast Back to School Asthma Study (0476-340)
This study, in children with chronic asthma, evaluates the number of days of worsening asthma during 8 weeks of treatment with montelukast after treatment is started for the first day of school.
- Trial name
- NCT00461032
- Testing
- montelukast
- Volunteers
- 1,162 people
- Sponsor
- Organon and Co
Asthma
Efficacy of CHF1535 Via NEXT DPI Versus pMDI and BDP DPI100µg on PeakExpiratoryFlow in Asthmatic Patients
The purpose of this study is to demonstrate that CHF 1535 NEXT DPI® is non-inferior to the corresponding dose of CHF 1535 pMDI and superior to marketed beclomethasone DPI 100 µg in terms of average pre-dose morning Peak…
- Trial name
- Neptune (NCT01345916)
- Testing
- CHF 1535 100/6 NEXT DPI® 2 months, CHF 1535 100/6 pMDI 2 months, BDP DPI 2 months
- Where
- Poland
- Volunteers
- 932 people
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
The primary objective of the study is to assess the efficacy of high dose fluticasone propionate (Fp)/albuterol sulfate (ABS) integrated electronic module multidose dry powder inhaler (eMDPI) compared to ABS eMDPI in decreasing…
- Trial name
- NCT06052267
- Testing
- TEV-56248, Albuterol sulfate
- Where
- 393 sites in United States, Argentina and 20 more
- Volunteers
- 2,772 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Asthma
Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy
The objective of this study is to compare healthcare utilization and costs in Medicare-eligible asthma patients (aged >65) who receive fluticasone propionate/salmeterol xinafoate combination or inhaled corticosteroids in a…
- Trial name
- NCT01347060
- Testing
- fluticasone propionate/salmeterol xinafoate combination, inhaled corticosteroids
- Volunteers
- 17,448 people
- Sponsor
- GlaxoSmithKline
Asthma
A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice
The main aim of the study to describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and…
- Trial name
- AIRITY (NCT07556159)
- Testing
- Procedure: Investigational Procedures
- Where
- 71 sites in United States, Canada and 3 more
- Volunteers
- 2,500 people
- Sponsor
- Sanofi
Asthma
A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma
The primary objective of this study is to demonstrate the effectiveness of the Digital System (DS) in improving asthma control compared to the Standard of Care (SoC) group.
- Trial name
- CONNECT2 (NCT04677959)
- Testing
- Fluticasone propionate/salmeterol (FS), Albuterol, Standard of Care Asthma Medication
- Where
- 46 sites in United States
- Volunteers
- 427 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Moderate-to-severe Allergic Asthma
A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
This study will assess the effect of omalizumab on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma.
- Trial name
- EDURO (NCT04195958)
- Testing
- Omalizumab
- Where
- 12 sites in United States
- Volunteers
- 3 people
- Sponsor
- Genentech, Inc.
Chronic Rhinosinusitis With Nasal Polyps, Asthma
EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients
Primary Objective -To evaluate the efficacy of dupilumab compared to omalizumab in reducing the polyp size and improving sense of smell Secondary Objectives To evaluate the efficacy of dupilumab in improving chronic…
- Trial name
- EVEREST (NCT04998604)
- Testing
- Dupilumab, Omalizumab
- Where
- 87 sites in United States, Belgium and 15 more
- Volunteers
- 360 people
- Sponsor
- Sanofi
Asthma
Safety & Efficacy of Symbicort® Turbuhaler® (1, 2, and 4 x 160/4.5 µg Twice Daily) in Japanese Patients With Asthma
This study is to confirm the safety of Symbicort® Turbuhaler® 160/4.5 µg 1, 2 or 4 inhalation b.i.d. over a 52 week treatment period in asthmatic patients who are being treated with IGCS and long acting β2-agonist (LABA) and/or…
- Trial name
- NCT00255255
- Testing
- Budesonide/Formoterol
- Where
- 18 sites in Japan
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Asthma
An Observational, Prospective, Multicenter Study to Evaluate the Biologic Use and Outcomes in Chinese Asthma Patients
This study is a multicenter, observational, prospective study to evaluate the asthma biologic use features and clinical outcomes in China.
- Trial name
- PRESENTII (NCT06605885)
- Where
- 29 sites in China
- Volunteers
- 202 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, Asthma
Efficacy and Safety of Tiotropium in Patients With COPD and Concomitant Diagnosis of Asthma
The primary objective of this study is to demonstrate the superiority of tiotropium compared to placebo in the treatment of patients with COPD and a concomitant diagnosis of asthma
- Trial name
- NCT00152984
- Testing
- Tiotropium inhalation capsules
- Where
- 68 sites in Belgium, Canada and 6 more
- Volunteers
- 472 people
- Sponsor
- Boehringer Ingelheim
Asthma
Integrated Digitally Enhanced Care for Long-term Conditions- Asthma
Asthma is a common lung condition that causes long term breathing difficulties. There is currently no cure for asthma but the use of simple inhaler treatments can keep the symptoms under control.
- Trial name
- IDEAL (NCT03511482)
- Testing
- myAsthma Application, Lloyds Pharmacy Online Doctor
- Where
- United Kingdom
- Sponsor
- my mhealth Ltd
Bronchial Asthma
A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice
This patient follow-up programme was designed to describe the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy in routine clinical practice in comparison with the already documented use…
- Trial name
- NCT00505388
- Where
- 695 sites in Belgium, Bulgaria and 10 more
- Volunteers
- 5,137 people
- Sponsor
- AstraZeneca
Asthma Bronchiale
Efficacy and Safety of Flutiform® pMDI in Adult Patients With Mild to Moderate-severe Reversible Asthma
Open, parallel group design. The study has a screening phase and a 12 week treatment phase. Subjects will be randomised to treatment in a 1:1 ration.
- Trial name
- NCT00476073
- Testing
- FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)
- Where
- United Kingdom
- Volunteers
- 228 people
- Sponsor
- Mundipharma Research Limited
Asthma
Study With GW274150 In Patients With Mild Asthma
This is a study investigating whether 14 days of dosing with GW274150 has a beneficial effect on a model of asthma type inflammation called the allergen-induced late asthmatic response.
- Trial name
- NCT00273013
- Testing
- GW274150, Singulair
- Where
- 2 sites in United Kingdom
- Volunteers
- 28 people
- Sponsor
- GlaxoSmithKline
Asthma
A Long-term Study of Ba253BINEB in Patients With Bronchial Asthma
The objective of this study is to investigate the long-term safety of Ba253BINEB. Secondarily the long-term efficacy of Ba253BINEB is also investigated.
- Trial name
- NCT02182661
- Testing
- Ba253BINEB
- Volunteers
- 88 people
- Sponsor
- Boehringer Ingelheim